Lexeo Therapeutics, Inc. (LXEO) shareholders
Close on Nov 17, 2026Market cap $234.24MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Balyasny Asset Management L.P. Joint filing with Bam Gp LLC (9.99%), Balyasny Asset Management Holdings LP (9.99%) and 2 more | 7,844,311 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 7,291,434 | 9.99% | 13G (passive) amendment | Nov 28, 2025 |
| Dmitry Balyasny Joint filing with Bam Gp LLC (9.89%), Balyasny Asset Management Holdings LP (9.89%) and 2 more | 7,221,555 | 9.89% | 13G (passive) amendment | Dec 31, 2025 |
| Balyasny Asset Management Holdings LP Joint filing with Bam Gp LLC (9.69%), Balyasny Asset Management L.P. (9.69%) and 2 more | 7,176,144 | 9.69% | 13G (passive) amendment | Mar 31, 2026 |
| Affinity Asset Advisors, LLC Joint filing with Michael Cho (8.40%) | 6,674,913 | 8.40% | 13G (passive) amendment | Jun 30, 2026 |
| Paradigm BioCapital Advisors LP Joint filing with Paradigm BioCapital Advisors GP LLC (8.30%), Senai Asefaw, M.D. (8.30%) and 1 more | 6,184,134 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (7.70%), Averill Master Fund, Ltd. (6.50%) | 5,674,778 | 7.70% | 13G (passive) | Apr 6, 2026 |
| James N. Topper Joint filing with Patrick J. Heron (9.90%), Albert Cha (8.30%) and 4 more | 5,500,812 | 9.90% | 13G (passive) | May 28, 2025 |
| Kenneth Griffin Joint filing with Citadel Advisors Holdings LP (7.20%), Citadel Advisors LLC (7.20%) and 1 more | 5,498,219 | 7.40% | 13G (passive) amendment | Dec 31, 2025 |
| Bam Gp LLC Joint filing with Balyasny Asset Management Holdings LP (9.99%), Balyasny Asset Management L.P. (9.99%) and 2 more | 5,394,721 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Michael Cho Joint filing with Affinity Asset Advisors, LLC (7.10%) | 5,217,660 | 7.10% | 13G (passive) amendment | Jan 22, 2026 |
| Rajeev Shah Joint filing with Peter Kolchinsky (6.90%), RA Capital Healthcare Fund, L.P. (6.90%) and 1 more | 5,000,000 | 6.90% | 13G (passive) | Oct 20, 2025 |
| BlackRock, Inc. | 4,885,814 | 6.70% | 13G (passive) | Dec 31, 2025 |
| JPMorgan Chase & Co. | 4,573,701 | 5.50% | 13G (passive) | Sep 30, 2026 |
| Paradigm BioCapital Advisors GP LLC Joint filing with Paradigm BioCapital Advisors LP (5.30%), Senai Asefaw, M.D. (5.30%) | 4,175,382 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
| Vestal Point Capital, LP Joint filing with Ryan Wilder (7.50%) | 4,117,302 | 7.50% | 13G (passive) amendment | Sep 30, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.L.C. (5.10%), Fhmlsp, L.P. (5.10%) | 3,698,271 | 5.10% | 13G (passive) amendment | Dec 31, 2025 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (6.00%) | 3,228,161 | 6.00% | 13G (passive) | Jun 30, 2025 |
| Millennium Management LLC Joint filing with Israel A. Englander (5.30%), Millennium Group Management LLC (5.30%) | 2,836,292 | 5.30% | 13G (passive) amendment | Jun 30, 2025 |
| Mizuho Financial Group, Inc. | 2,203,631 | 6.60% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LXEO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6,384,200 | 7.78% | $29.72M | +5,134,200 | 0.54% |
| Affinity Asset Advisors, LLC | 5,807,611 | 7.08% | $27.03M | +757,400 | 1.22% |
| BlackRock, Inc. | 5,739,455 | 7.00% | $26.72M | +628,584 | 0.00% |
| Ra Capital Management, L.P. | 5,000,000 | 6.09% | $23.28M | – | 0.20% |
| Frazier Life Sciences Management, L.P. | 4,824,725 | 5.88% | $22.46M | +400,000 | 0.49% |
| State Street Corp | 4,354,757 | 5.31% | $20.27M | +786,515 | 0.00% |
| Vestal Point Capital, LP | 4,320,000 | 5.27% | $20.11M | −155,000 | 0.47% |
| Paradigm Biocapital Advisors LP | 4,175,382 | 5.09% | $19.44M | −2,008,752 | 0.36% |
| Jupiter Topco LLC | 3,954,691 | 4.82% | $18.41M | New | 0.01% |
| Orbimed Advisors LLC | 3,947,850 | 4.81% | $18.38M | +345,400 | 0.34% |
| Citadel Advisors LLC | 3,898,570 | 4.75% | $18.15M | +63,571 | 0.00% |
| Vanguard Capital Management LLC | 3,125,893 | 3.81% | $14.55M | +118,800 | 0.00% |
| Millennium Management LLC | 2,833,622 | 3.45% | $13.19M | +1,220,842 | 0.00% |
| Nantahala Capital Management, LLC | 2,600,000 | 3.17% | $12.10M | +1,400,000 | 0.20% |
| Woodline Partners LP | 2,500,532 | 3.05% | $11.64M | −250,000 | 0.04% |
| Balyasny Asset Management L.P. | 2,412,742 | 2.94% | $11.23M | +823,157 | 0.01% |
| Goldman Sachs Group Inc | 2,149,612 | 2.62% | $10.01M | +199,727 | 0.00% |
| 683 Capital Management, LLC | 1,875,000 | 2.29% | $8.73M | +675,000 | 0.43% |
| Geode Capital Management, LLC | 1,747,959 | 2.13% | $8.14M | +234,182 | 0.00% |
| ADAR1 Capital Management, LLC | 1,565,950 | 1.91% | $7.29M | +98,600 | 0.33% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 142 | 90M | 100.0% | 28 / 59 | 39 / 22 | 21M | 7M |
| Q1 2026 | 139 | 80M | 97.4% | 21 / 58 | 38 / 27 | 15M | 8M |
| Q4 2025 | 146 | 76M | 93.2% | 47 / 61 | 26 / 9 | 34M | 7M |
| Q3 2025 | 109 | 49M | 60.1% | 26 / 50 | 15 / 7 | 10M | 3M |
| Q2 2025 | 90 | 42M | 51.5% | 17 / 36 | 17 / 15 | 19M | 5M |
| Q1 2025 | 88 | 28M | 34.1% | 17 / 25 | 23 / 18 | 4M | 6M |
| Q4 2024 | 90 | 30M | 36.0% | 29 / 29 | 12 / 8 | 4M | 4M |
| Q3 2024 | 69 | 30M | 36.4% | 16 / 36 | 9 / 6 | 8M | 4M |
| Q2 2024 | 60 | 27M | 32.4% | 15 / 27 | 13 / 9 | 5M | 1M |
| Q1 2024 | 54 | 23M | 28.2% | 28 / 18 | 5 / 5 | 7M | 0M |
| Q4 2023 | 31 | 16M | 19.7% | 31 / 0 | 0 / 0 | 16M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
138 funds held LXEO in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LXEO | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,429,592 | 2.96% | $11.31M | 0.11% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,335,144 | 2.85% | $10.87M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,846,016 | 2.25% | $8.59M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 776,529 | 0.95% | $3.21M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 715,413 | 0.87% | $3.33M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 665,326 | 0.81% | $3.10M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 566,200 | 0.69% | $2.64M | 0.09% | Jun 30, 2026 |
| Janus Henderson Global Life Sciences Fund | 561,264 | 0.68% | $2.61M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 435,053 | 0.53% | $2.03M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 339,114 | 0.41% | $1.74M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 308,002 | 0.38% | $1.58M | 0.00% | May 31, 2026 |
| Small Cap Value Fund | 261,109 | 0.32% | $1.22M | 0.18% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 254,051 | 0.31% | $1.05M | 0.01% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 238,249 | 0.29% | $1.11M | 0.07% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 232,132 | 0.28% | $958.71K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard Nolan Townsend | Chief Executive Officer, Director | 376,778 | 0.46% | Sep 28, 2026 |
| Narinder Pal Bhalla | Chief Medical Officer | 84,908 | 0.10% | Sep 28, 2026 |
| Jose Manuel Otero | Chief Operating Officer | 138,288 | 0.17% | Sep 28, 2026 |
| Louis Edward Tamayo | Chief Financial Officer | 92,907 | 0.11% | Sep 28, 2026 |
| Eric Adler | Chief Medical Officer | 72,646 | 0.09% | Nov 20, 2025 |
| Jenny Robertson | Chief Legal Officer | 68,381 | 0.08% | Nov 20, 2025 |
| Tai Sandi See | Chief Development Officer | 65,476 | 0.08% | Nov 20, 2025 |
| Kyle Rasbach | Chief Financial Officer | 40,875 | 0.05% | Jan 22, 2025 |
| Tobin Schilke | Director | – | – | Nov 17, 2026 |
| Brenda Cooperstone | Director | – | – | Jun 29, 2026 |
| Tolga Tanguler | Director | – | – | Jun 29, 2026 |
| Mette Kirstine Agger | Director | – | – | Jun 29, 2026 |
| Reinaldo M. Diaz | Director | – | – | Jun 29, 2026 |
| Paula H. Cholmondeley | Director | 30,627 | 0.04% | Jun 29, 2026 |
| Hauwermeiren Timothy Van | Director | – | – | Jun 29, 2026 |
| Steven Altschuler | Director | – | – | Jun 29, 2026 |
| Laura Sepp-Lorenzino | Director | – | – | Apr 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jose Manuel Otero Chief Operating Officer | Sep 14, 2026 | Award | +2,110 | $2.64 | $5.57K | 138,288 |
| Narinder Pal Bhalla Chief Medical Officer | Sep 14, 2026 | Award | +2,714 | $3.58 | $9.72K | 84,908 |
| Richard Nolan Townsend Chief Executive Officer, Director | Sep 14, 2026 | Award | +2,306 | $2.64 | $6.09K | 376,778 |
| Louis Edward Tamayo Chief Financial Officer | Aug 18, 2026 | Sale | −4,117 | $4.91 | $20.21K | 92,907 |
| Jose Manuel Otero Chief Operating Officer | Aug 18, 2026 | Sale | −1,304 | $4.96 | $6.47K | 136,178 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2026 | Sale | −3,345 | $4.95 | $16.56K | 374,472 |
| Richard Nolan Townsend Chief Executive Officer, Director | Jul 1, 2026 | Sale | −25,947 | $4.48 | $116.24K | 377,817 |
| Louis Edward Tamayo Chief Financial Officer | Jul 1, 2026 | Sale | −4,641 | $4.49 | $20.84K | 97,024 |
| Narinder Pal Bhalla Chief Medical Officer | Jul 1, 2026 | Sale | −22,306 | $4.42 | $98.59K | 82,194 |
| Jose Manuel Otero Chief Operating Officer | Jul 1, 2026 | Sale | −4,666 | $4.48 | $20.90K | 137,482 |
| Richard Nolan Townsend Chief Executive Officer, Director | Jun 29, 2026 | Award | +67,000 | – | – | 403,764 |
| Louis Edward Tamayo Chief Financial Officer | Jun 29, 2026 | Award | +12,000 | – | – | 101,665 |
| Narinder Pal Bhalla Chief Medical Officer | Jun 29, 2026 | Award | +55,000 | – | – | 104,500 |
| Jose Manuel Otero Chief Operating Officer | Jun 29, 2026 | Award | +12,060 | – | – | 142,148 |
| Richard Nolan Townsend Chief Executive Officer, Director | May 18, 2026 | Sale | −3,342 | $5.06 | $16.91K | 336,764 |
| Jose Manuel Otero Chief Operating Officer | May 18, 2026 | Sale | −1,302 | $5.07 | $6.60K | 130,088 |
| Richard Nolan Townsend Chief Executive Officer, Director | Apr 6, 2026 | Sale(10b5-1 plan) | −55,000 | $5.69 | $312.95K | 340,106 |
| Richard Nolan Townsend Chief Executive Officer, Director | Mar 13, 2026 | Award | +2,623 | $2.64 | $6.92K | 395,106 |
| Jose Manuel Otero Chief Operating Officer | Mar 13, 2026 | Award | +5,930 | $2.64 | $15.66K | 131,390 |
| Jose Manuel Otero Chief Operating Officer | Feb 18, 2026 | Sale | −3,016 | $6.40 | $19.30K | 125,460 |
| Richard Nolan Townsend Chief Executive Officer, Director | Feb 18, 2026 | Sale | −10,173 | $6.38 | $64.90K | 392,483 |
| Narinder Pal Bhalla Chief Medical Officer | Feb 13, 2026 | Award | +49,500 | – | – | 49,500 |
| Louis Edward Tamayo Chief Financial Officer | Feb 4, 2026 | Award | +44,665 | – | – | 89,665 |
| Richard Nolan Townsend Chief Executive Officer, Director | Feb 4, 2026 | Award | +161,665 | – | – | 402,656 |
| Jose Manuel Otero Chief Operating Officer | Feb 4, 2026 | Award | +65,000 | – | – | 128,476 |
| Jose Manuel Otero Chief Operating Officer | Nov 18, 2025 | Sale | −721 | $9.27 | $6.68K | 63,476 |
| Tai Sandi See Chief Development Officer | Nov 18, 2025 | Sale | −386 | $9.27 | $3.58K | 65,476 |
| Eric Adler Chief Medical Officer | Nov 18, 2025 | Sale | −615 | $9.27 | $5.70K | 72,646 |
| Richard Nolan Townsend Chief Executive Officer, Director | Nov 18, 2025 | Sale | −1,127 | $9.27 | $10.45K | 240,991 |
| Jenny Robertson Chief Legal Officer | Nov 18, 2025 | Sale | −549 | $9.27 | $5.09K | 68,381 |
| Eric Adler Chief Medical Officer | Oct 17, 2025 | Sale | −3,344 | $8.94 | $29.90K | 73,299 |
| Eric Adler Chief Medical Officer | Oct 17, 2025 | Sale | −38 | $9.56 | $363 | 73,261 |
| Tai Sandi See Chief Development Officer | Oct 17, 2025 | Sale | −3,844 | $8.94 | $34.37K | 65,906 |
| Tai Sandi See Chief Development Officer | Oct 17, 2025 | Sale | −44 | $9.56 | $421 | 65,862 |
| Jose Manuel Otero Chief Technical Officer | Oct 17, 2025 | Sale | −24 | $9.56 | $229 | 64,197 |
| Jose Manuel Otero Chief Technical Officer | Oct 17, 2025 | Sale | −2,091 | $8.94 | $18.69K | 64,221 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 17, 2025 | Sale | −148 | $9.56 | $1.41K | 242,118 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 17, 2025 | Sale | −12,985 | $8.94 | $116.09K | 242,266 |
| Jenny Robertson Chief Legal Officer | Oct 17, 2025 | Sale | −3,486 | $8.94 | $31.16K | 68,970 |
| Jenny Robertson Chief Legal Officer | Oct 17, 2025 | Sale | −40 | $9.56 | $382 | 68,930 |
| Eric Adler Chief Medical Officer | Oct 15, 2025 | Award | +9,570 | – | – | 76,643 |
| Tai Sandi See Chief Development Officer | Oct 15, 2025 | Award | +10,890 | – | – | 69,750 |
| Jose Manuel Otero Chief Technical Officer | Oct 15, 2025 | Award | +5,940 | – | – | 66,312 |
| Richard Nolan Townsend Chief Executive Officer, Director | Oct 15, 2025 | Award | +33,000 | – | – | 255,251 |
| Jenny Robertson Chief Legal Officer | Oct 15, 2025 | Award | +9,900 | – | – | 72,456 |
| Richard Nolan Townsend Chief Executive Officer, Director | Sep 12, 2025 | Award | +2,193 | $2.64 | $5.79K | 222,251 |
| Louis Edward Tamayo Chief Financial Officer | Aug 29, 2025 | Award | +45,000 | – | – | 45,000 |
| Jose Manuel Otero Chief Technical Officer | Aug 18, 2025 | Sale | −721 | $9.27 | $6.68K | 63,476 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2025 | Sale | −1,115 | $4.67 | $5.21K | 220,058 |
| Tai Sandi See Chief Development Officer | Aug 18, 2025 | Sale | −382 | $4.67 | $1.78K | 58,860 |
| Richard Nolan Townsend Chief Executive Officer, Director | Aug 18, 2025 | Sale | −2,735 | $4.67 | $12.77K | 220,058 |
| Jose Manuel Otero Chief Technical Officer | Aug 18, 2025 | Sale | −2,848 | $4.67 | $13.30K | 60,372 |
| Jenny Robertson Chief Legal Officer | Aug 18, 2025 | Sale | −542 | $4.67 | $2.53K | 62,556 |
| Eric Adler Chief Medical Officer | Aug 18, 2025 | Sale | −608 | $4.67 | $2.84K | 67,073 |
| Eric Adler Chief Medical Officer | May 16, 2025 | Sale | −585 | $2.77 | $1.62K | 67,681 |
| Jenny Robertson Chief Legal Officer | May 16, 2025 | Sale | −521 | $2.77 | $1.44K | 63,098 |
| Richard Nolan Townsend Chief Executive Officer, Director | May 16, 2025 | Sale | −1,074 | $2.77 | $2.97K | 221,173 |
| Tai Sandi See Chief Development Officer | May 16, 2025 | Sale | −367 | $2.77 | $1.02K | 59,242 |
| Jose Manuel Otero Chief Technical Officer | Mar 14, 2025 | Award | +5,720 | $2.61 | $14.93K | 63,220 |
| Jenny Robertson Chief Legal Officer | Mar 14, 2025 | Award | +5,720 | $2.61 | $14.93K | 63,619 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexeo Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,471 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard Nolan Townsend Officer, Director | Aug 18, 2026 | 3,345 | $16.56K | Aug 18, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | Aug 18, 2026 | 1,304 | $6.46K | Aug 18, 2026 | Restricted Stock Vesting |
| Louis Edward Tamayo Officer | Aug 18, 2026 | 4,117 | $20.20K | Aug 18, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | Jul 1, 2026 | 25,947 | $116.19K | Jul 1, 2026 | Restricted Stock Vesting |
| Narinder Pal Bhalla Officer | Jul 1, 2026 | 22,306 | $98.68K | Jul 1, 2026 | Restricted Stock Vesting |
| Louis Edward Tamayo Officer | Jul 1, 2026 | 4,641 | $20.81K | Jul 1, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | Jul 1, 2026 | 4,666 | $20.92K | Jul 1, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | May 18, 2026 | 3,342 | $16.93K | May 18, 2026 | Restricted Stock Vesting |
| Jose Manuel Otero Officer | May 18, 2026 | 1,302 | $6.61K | May 18, 2026 | Restricted Stock Vesting |
| Eric Adler Officer | May 18, 2026 | 1,595 | $8.07K | May 18, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Director, Officer | Apr 6, 2026 | 55,000 | $314.60K | Apr 6, 2026 | CS-3 Incentive Units |
| Tai Sandi See Officer | Feb 18, 2026 | 3,861 | $24.68K | Feb 18, 2026 | Restricted Stock Vesting |
| Richard Nolan Townsend Officer, Director | Feb 18, 2026 | 11,374 | $72.59K | Feb 18, 2026 | Restricted Stock Vesting |
| Eric Adler Officer | Feb 18, 2026 | 4,867 | $31.14K | Feb 18, 2026 | Restricted Stock Vesting |
| Jenny Robertson Officer | Feb 18, 2026 | 3,736 | $23.90K | Feb 18, 2026 | Restricted Stock Vesting |
See a number that looks wrong?